A more common, intermediate effect variant in FHOD3 (p.Arg637Gln; gnomAD NFE AF 0.03%) has been associated with a clinically aggressive course and an earlier presentation in homozygous carriers, consolidating the association between FHOD3 and the development of HCM [133]. This evidence concerns the gene FHOD3 and atrial fibrillation.